Neil Kumar - May 16, 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Chief Executive Officer, Director
Signature
/s/ Neil Kumar
Stock symbol
BBIO
Transactions as of
May 16, 2025
Transactions value $
-$4,488,520
Form type
4
Date filed
5/20/2025, 06:06 PM
Previous filing
Apr 24, 2025
Next filing
Jul 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kumar Neil Chief Executive Officer, Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Neil Kumar 2025-05-20 0001742485

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +64.7K +30.56% 276K May 16, 2025 Direct F1
transaction BBIO Common Stock Tax liability -$1.11M -32.9K -11.89% $33.84 244K May 16, 2025 Direct F2
transaction BBIO Common Stock Sale -$858K -25.8K -10.57% $33.32 218K May 19, 2025 Direct F3, F4
transaction BBIO Common Stock Sale -$13.5K -400 -0.18% $33.75 217K May 19, 2025 Direct F3, F5
transaction BBIO Common Stock Sale -$2.5M -75K -1.54% $33.40 4.8M May 20, 2025 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. F3, F6, F7
holding BBIO Common Stock 996K May 16, 2025 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -33.5K -12.5% $0.00 235K May 16, 2025 Common Stock 33.5K Direct F1, F8
transaction BBIO Restricted Stock Units Options Exercise $0 -19.6K -8.33% $0.00 216K May 16, 2025 Common Stock 19.6K Direct F1, F9
transaction BBIO Restricted Stock Units Options Exercise $0 -11.6K -6.25% $0.00 173K May 16, 2025 Common Stock 11.6K Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,696 shares of Common Stock underlying the Reporting Person's RSUs.
F3 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F4 Represents the weighted average sale price of the shares sold from $32.72 to $33.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5 Represents the weighted average sale price of the shares sold from $33.72 to $33.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F6 Represents the weighted average sale price of the shares sold from $33.02 to $33.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F7 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F8 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F9 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F10 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.